The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1549
June 18, 2018
View Complete Issue         Table of Contents 2019 
Andexxa - An Antidote for Apixaban and Rivaroxaban
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Andexxa - An Antidote for Apixaban and Rivaroxaban
June 18, 2018 (Issue: 1549)
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Andexxa - An Antidote for Apixaban and Rivaroxaban
Article code: 1549a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.